Library
Celyad Reports Full Year 2019 Financial Results and Provides Business Update
Celyad Reports Full Year 2019 Financial Results and Provides Business Update
Celyad to Announce Full Year 2019 Financial Results and Host Conference Call
Celyad to Announce Full Year 2019 Financial Results and Host Conference Call
Celyad Appoints Stephen Rubino as Chief Business Officer
Celyad Appoints Stephen Rubino as Chief Business Officer
Celyad Announces February and March 2020 Conference Schedule
Celyad Announces February and March 2020 Conference Schedule
Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS
Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS
Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting
Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting
Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo
Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien
Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien
Development of the Next Generation NKG2D CAR T-cell Manufacturing Process
Development of the Next Generation NKG2D CAR T-cell Manufacturing Process